Takeda Announces Discontinuation of Two of its Hemophilia Treatments: HEMOFIL® M and RECOMBINATE®
On March 18, 2025, Takeda Pharmaceuticals announced it will globally discontinue two of its hemophilia treatments: HEMOFIL® M [Antihemophilic Factor (Human), Method M, Monoclonal Purified] and RECOMBINATE® [Antihemophilic Factor (Recombinant)]. According to Takeda’s letter to patients, the company will continue to supply both medications to current patients until inventory is depleted or expires in mid-2026. The exact timing will vary based on potency and demand. Takeda has emphasized there are no quality or safety issues with either product.
In their announcement, Anthea Cherednichenko, Vice President and Franchise Head of U.S. Hematology at Takeda, wrote: “This was not a decision we made lightly. As the treatment landscape evolves, we decided to discontinue these medicines as hemophilia patients continue to transition to alternate treatment options in the space, including those within our own hematology portfolio.”
If you or a family member currently uses either HEMOFIL® M [Antihemophilic Factor (Human), Method M, Monoclonal Purified] or RECOMBINATE® [Antihemophilic Factor (Recombinant)], we recommend contacting your healthcare provider to discuss your specific situation and develop a transition plan. Takeda will continue supplying these medications until mid-2026, so there’s time to consider your options carefully. It’s important not to make any immediate changes to your treatment regimen without proper medical guidance from your healthcare team.
Regarding alternative options, Takeda is directing patients to discuss treatment plans with their healthcare providers. The company has highlighted its two other factor VIII products as potential alternatives: ADVATE® [Antihemophilic Factor (Recombinant)] and ADYNOVATE® [Antihemophilic Factor (Recombinant), PEGylated]. Both remaining treatments are indicated for the treatment and control of bleeding in children and adults with hemophilia A (congenital factor VIII deficiency). You can find more information about these options at ADVATE.com and ADYNOVATE.com.
We also encourage you to register for the Patient Notification System (PNS) if you haven’t already. By signing up, you’ll receive immediate alerts directly to your phone or email about any recalls or withdrawals of bleeding disorders therapies–ensuring you’re always informed about changes that could affect your treatment.
NBDF remains dedicated to keeping our bleeding disorders community informed about important developments. We continuously monitor changes in treatment options, healthcare policies, medication recalls, and access issues that may impact your care. To ensure you receive these critical updates as they happen, we encourage you to connect with NBDF through our website, newsletter, and social media channels.
Takeda has established several support resources for affected patients. General information is available at HemophiliaJourney.com. Financial assistance options and insurance support can be accessed through Takeda Patient Support at TakedaPatientSupport.com or by calling 1-888-229-8379. Any adverse reactions and quality issues can be reported at 1-877-TAKEDA-7 (1-877-825-3327).